Domain Therapeutics
About:
Domain Therapeutics develops small molecules targeting G-coupled protein receptors.
Website: http://www.domaintherapeutics.com
Twitter/X: domaintherapeut
Top Investors: Andera Partners, Bpifrance, Seventure Partners, adMare Bio Innovations, Airfi aero
Description:
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
$100M
$1M to $10M
Illkirch, Alsace, France
2001-01-01
contact(AT)domaintherapeutics.com
Pascal Neuville
101-250
2024-01-25
Private
© 2025 bioDAO.ai